Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Revance Therapeutics, Inc. | 84,686 | reported | 06 Feb 2025 | tx 51+3,877,148−1,823,128 |
| SI-BONE, Inc. | 8,797 | reported | 16 Jun 2020 | tx 2+35,033 |
| GLAUKOS Corp | 2,987 | reported | 28 May 2026 | tx 28+147,896−75,247 |
| Zeltiq Aesthetics Inc | 0 | reported | 28 Apr 2017 | tx 175+3,146,866−3,380,758 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 28 May 2026 | GRANT_AWARD | GLAUKOS Corp | 1,878 | 0.00 USD | |
| 28 May 2026 | GRANT_AWARD | GLAUKOS Corp | 2,987 | 0.00 USD | deriv |
| 02 Jan 2026 | GRANT_AWARD | GLAUKOS Corp | 1,168 | 0.00 USD | |
| 02 Jan 2025 | GRANT_AWARD | GLAUKOS Corp | 864 | 0.00 USD | |
| 29 May 2025 | GRANT_AWARD | GLAUKOS Corp | 2,108 | 0.00 USD | |
| 29 May 2025 | GRANT_AWARD | GLAUKOS Corp | 3,149 | 0.00 USD | deriv |
| 26 Feb 2025 | EXERCISE | GLAUKOS Corp | 15,000 | 24.69 USD | |
| 26 Feb 2025 | EXERCISE | GLAUKOS Corp | 25,000 | 32.00 USD | |
| 26 Feb 2025 | SALE | GLAUKOS Corp | 20,687 | 120.72 USD | |
| 26 Feb 2025 | EXERCISE | GLAUKOS Corp | 25,000 | 0.00 USD | deriv |
| 26 Feb 2025 | EXERCISE | GLAUKOS Corp | 15,000 | 0.00 USD | deriv |
| 06 Feb 2025 | GRANT_AWARD | Revance Therapeutics, Inc. | 84,686 | 0.00 USD | |
| 04 Feb 2025 | TENDER | Revance Therapeutics, Inc. | 996,935 | 3.65 USD | |
| 04 Feb 2025 | TENDER | Revance Therapeutics, Inc. | 110,913 | 3.65 USD | |
| 06 Feb 2025 | OTHER | Revance Therapeutics, Inc. | 27,933 | — | |
| 06 Feb 2025 | OTHER | Revance Therapeutics, Inc. | 84,686 | — | |
| 03 Feb 2025 | GRANT_AWARD | Revance Therapeutics, Inc. | 27,933 | 0.00 USD | |
| 31 Dec 2024 | GRANT_AWARD | Revance Therapeutics, Inc. | 1,000 | 2.18 USD | |
| 30 Jun 2024 | GRANT_AWARD | Revance Therapeutics, Inc. | 1,000 | 2.18 USD | |
| 30 May 2024 | GRANT_AWARD | GLAUKOS Corp | 1,716 | 0.00 USD | |
| 30 May 2024 | GRANT_AWARD | GLAUKOS Corp | 1,246 | 0.00 USD | deriv |
| 15 Mar 2024 | TAX_WITHHOLDING | Revance Therapeutics, Inc. | 3,305 | 5.31 USD | |
| 15 Mar 2024 | TAX_WITHHOLDING | Revance Therapeutics, Inc. | 17,228 | 5.31 USD | |
| 06 Mar 2024 | PURCHASE | Revance Therapeutics, Inc. | 30,000 | 6.98 USD | first after silence |
| 29 Feb 2024 | GRANT_AWARD | Revance Therapeutics, Inc. | 70,750 | 0.00 USD |
2 purchases reported after at least 12 months of silence — most recent on 06 Mar 2024.